Company intelligence / Profile preview

Angiex

Cambridge, Massachusetts, United Statesangiex.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Angiex has initiated a first-in-human, open-label Phase I trial of its lead candidate AGX101, a novel ND‑ADC targeting TM4SF1. The trial aims to assess safety, pharmacokinetics, and preliminary anti-tumor activity in patients with solid tumors. Preclinical data demonstrated selective killing of both tumor cells and tumor endothelial cells with no known resistance mechanisms. The company’s approach may offer new hope for aggressive cancers resistant to existing therapies[6][8][10].

Therapeutic areas: OncologyCardiovascular
Modalities: Antibody-drug conjugates (ADCs)Nuclear-delivered ADCs (ND-ADCs)
Industry: Biotech

Drug pipeline

3 assets

AGX101

2 more assets in the full pipeline.

Request access →

Partnerships

Abzena (CDMO partner for bioconjugation and cGMP manufacturing of AGX101 clinical material)[6]Outlicensing plans to pharma/biotech partners for vascular indications[7]

Beyond the preview

Go deeper on Angiex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiex.

Explore the full profile